Lerner's UV light therapy for psoriasis gets FDA clearance
This article was originally published in Clinica
Executive Summary
Lerner Medical Devices' Levia, an at-home light therapy device, has received US FDA 510(k) clearance for the treatment of psoriasis. The product uses ultraviolet B (UVB) light to slow the growth of affected skin cells, and is designed to treat psoriasis of the scalp and small flare-ups of the disease. It can also be used in other skin conditions such as vitiligo, which causes depigmentation of patches of skin. The Levia system has delivery attachments, the Lite-Brush and Lite-Spot, which direct the UVB light to affected areas and minimise exposure of healthy skin. Lerner (Los Angeles, California) plans to launch the product this quarter.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.